# EAA232 (NCT06948084)

> Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06948084
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Recurrent Multiple Myeloma; Refractory Multiple Myeloma
- Interventions: Biospecimen Collection; Bone Marrow Biopsy; Carfilzomib; Computed Tomography; Daratumumab and Recombinant Human Hyaluronidase; Dexamethasone; FDG-Positron Emission Tomography; Pomalidomide; Teclistamab
- Enrollment: 80
- Primary outcome: Minimal residual disease (MRD) negativity

## Indexed commentary on EAA232 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=eaa232-nct06948084